Preexisting ulcerative colitis increases the risk of immune-related colitis and predicts divergent survival outcomes in gastrointestinal cancer patients treated with immune checkpoint inhibitors
For preexisting UC patients treated with ICIs, the risk of IRC is increased. Mild IRC may suggest a favorable prognosis, and being vigilant and effectively managing the occurrence of severe IRC is crucial for maximizing clinical benefits. Targeting the IL-6 pathway may be a potential new strategy for treating IRC in the future.
Authors
- Hui Tao (ORCID: https://orcid.org/0000-0002-6493-2101)
- Liuying Li (ORCID: https://orcid.org/0000-0001-7826-1276)
- Yunzhe Wang (ORCID: https://orcid.org/0000-0003-0599-6989)
- Qiling Zhou (ORCID: https://orcid.org/0000-0001-6639-8590)
- Zhengzheng Ji
- Lu Chen (ORCID: https://orcid.org/0000-0002-6208-1438)
- Jingjing Wu (ORCID: https://orcid.org/0000-0002-6396-817X)
- Zhao Yuanyi
- Hanlong Zhu (ORCID: https://orcid.org/0000-0002-8712-2734)
- Fangyu Wang
- Kaixuan Liu (ORCID: https://orcid.org/0000-0001-7506-4285)
- Shuo Xu (ORCID: https://orcid.org/0000-0002-7839-8552)
Institutions
- Hebei Medical University (CN)
- Fourth Hospital of Hebei Medical University (CN)
- People's Hospital of Cangzhou (CN)
- Second Affiliated Hospital of Nanjing Medical University (CN)
- Nanjing Medical University (CN)
- Nanjing University (CN)
Publication Details
- Journal
- Frontiers in Immunology
- Published
- 2025-08-13
- DOI
- https://doi.org/10.3389/fimmu.2025.1627680
- Primary Topic
- Cancer Immunotherapy and Biomarkers
- Type
- article
- Field-Weighted Citation Impact
- 0.00
Funders
- National Natural Science Foundation of China